Prostate Cancer - Results from #80

Profiling of Urinary Extracellular Vesicle Protein Signatures from Patients with Cribriform and Intraductal Prostate Carcinoma in a Cross-Sectional Study - Beyond the Abstract January 2, 2025

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors - Beyond the Abstract December 19, 2024

Prostate-Specific Antigen at 3 Months as a Predictor of Radiologic Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer Treated with Apalutamide: Analysis of 633 Patients in a Real-World Database - Beyond the Abstract December 18, 2024

Oncologic Outcomes of Incidental Versus Biopsy-Diagnosed Grade Group 1 Prostate Cancer: A Multi-Institutional Study - Beyond the Abstract December 18, 2024

The Rapidly Evolving Treatment Landscape of Metastatic Hormone-Sensitive Prostate Cancer - Beyond the Abstract December 18, 2024

Adiposity and Muscle Strength in Men With Prostate Cancer and Cardiovascular Outcomes - Beyond the Abstract December 17, 2024

Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom, and France - Beyond the Abstract December 16, 2024

A Pilot Study of AI-Assisted Reading of Prostate MRI in Organized Prostate Cancer Testing - Beyond the Abstract December 12, 2024

Coagulation Factor X Promotes Resistance to Androgen-Deprivation Therapy in Prostate Cancer - Beyond the Abstract December 11, 2024

Docetaxel Versus Androgen-Receptor Signaling Inhibitors as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract December 9, 2024

Impact of TP53 Loss-of-Function Alterations on the Response to PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract November 27, 2024

Evaluating 4Kscore's Role in Predicting Progression on Active Surveillance for Prostate Cancer Independently of Clinical Information and PIRADS Score - Beyond the Abstract November 26, 2024

Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis - Beyond the Abstract November 26, 2024

CDK12 Loss Drives Prostate Cancer Progression, Transcription-Replication Conflicts, and Synthetic Lethality with Paralog CDK13 - Beyond the Abstract November 21, 2024

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data - Beyond the Abstract November 19, 2024

Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma - Beyond the Abstract November 18, 2024

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract November 14, 2024

PSMA PET/CT for Treatment Response Evaluation at Predefined Time Points Is Superior to PSA Response for Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients - Beyond the Abstract November 8, 2024

PSMA PET Improves Characterization of Dural-Based Intracranial Lesions in Patients with Metastatic Prostate Cancer - Beyond the Abstract November 7, 2024

Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival - Beyond the Abstract November 6, 2024

Page 5 of 62